Table 3.
Pain prevalence in patients with curative treatment (Group 2) (n = 34).
| % Pain | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Quality | Continent a | Setting b | Cancer c | Mean Age | Sample | None | Mild | Moderate | ModSev d | Severe | Overall |
| Andersen, 2014 [34] | 16 | 2 | 2 | 5 | 133 | 20 | 26 | 78 | ||||
| Berliere–a, 2021 [53] Berliere–b, 2021 [53] |
16 16 |
2 2 |
1,2 1,2 |
5 5 |
53 | 32 31 |
46.0 29.0 |
|||||
| Bretschneider, 2016 [54] | 16 | 1 | 2 | 9 | 58.1 | 152 | 53.4 | 29.7 | 8.8 | 16.9 | 8.1 | 46.6 |
| Browall, 2017 [55] | 17 | 2 | 2 | 5 | 59 | 124 | 67 | |||||
| Calderon, 2019 [56] | 15 | 2 | 2 | 5 | 53.2 | 240 | 4.2 | |||||
| Choo, 2019 [57] | 17 | 3 | 2 | 5 | 60.35 | 192 | 59.9 | |||||
| de Menezes Couceiro, 2014 [58] | 16 | 4 | 2 | 5 | 54 | 250 | 44.4 | |||||
| Dylke, 2015 [59] | 15 | 6 | 2 | 5 | 55 | 157 | 83 | |||||
| El-Aqoul, 2018 [60] | 17 | 3 | 1 | 1 | 47.6 | 800 | 43.6 e | 56.4 | ||||
| Fenlon, 2014 [61] | 16 | 2 | 2 | 5 | 57 | 455 | 53 | |||||
| Fjell, 2020 [62] | 16 | 2 | 2 | 5 | 49 | 150 | 42.5 | |||||
| Hagiwara–a, 2018 [63] Hagiwara–b, 2018 [63] |
19 19 |
3 3 |
2 2 |
6 6 |
178 176 |
42.0 41.0 |
||||||
| Haryani, 2018 [64] | 16 | 3 | 2 | 1 | 50.51 | 207 | 38.2 | 17.9 | 22.7 | 4.8 | 60.87 | |
| Ho, 2015 [65] | 15 | 3 | 2 | 5 | 49 | 133 | 24 | |||||
| Hong, 2014 [66] | 16 | 3 | 1 | 1 | 51.24 | 1217 | 88 | 12 | ||||
| Jarden, 2021 [67] | 16 | 2 | 1 | 10 | 53.1 | 70 | 55.2 | |||||
| Jensen, 2018 [68] | 17 | 2 | 2 | 9 | 49 | 1176 | 60.6 | 26.8 | 9.1 | 12.6 | 3.5 | 39.4 |
| Khan–a, 2017 [69] Khan–b, 2017 [69] |
15 15 |
1 1 |
2 2 |
5 5 |
62 60.5 |
80 80 |
36 50 |
30 20 |
30 26 |
30 27 |
0 1 |
60 47 |
| Kim, 2016 [70] | 16 | 3 | 1 | 5 | 50.3 | 1499 | 8.8 e | 91.2 | ||||
| Kirchheiner, 2015 [41] | 17 | 2 | 2 | 9 | 50 | 42.0 | ||||||
| Kirkham, 2018 [71] | 15 | 1 | 1 | 5 | 50 | 24 | 54 | |||||
| Lewis, 2015 [72] | 16 | 6 | 2 | 1 | 61 | 276 | 55.0 | |||||
| Lewis, 2021 [73] | 18 | 3 | 2 | 2 | 600 | 45.2 | ||||||
| McFarland, 2018 [74] | 15 | 1 | 2 | 5 | 55.4 | 125 | 19.5 | |||||
| Moloney, 2016 [75] | 16 | 6 | 1 | 5 | 54.2 | 121 | 24 | 46.2 | ||||
| Nogueira de Oliveira Martins–a, 2017 [76] Nogueira de Oliveira Martins–b, 2017 [76] |
17 17 |
4 4 |
2 2 |
5 5 |
49.6 49.6 |
11 11 |
90.9 72.2 |
|||||
| Okamoto, 2018 [77] | 17 | 3 | 2 | 5 | 59 | 123 | 48.8 | 42.3 | 8.9 | 14 | 5.1 | 51.2 |
| Ribas, 2020 [78] | 15 | 2 | 2 | 9 | 65 | 109 | 20.1 | |||||
| Røhrl, 2016 [79] | 17 | 2 | 2 | 6 | 60.7 | 68 | 44.1 | |||||
| Shaulov, 2019 [80] | 16 | 1 | 1,2 | 10 | 49.1 | 318 | 51.3 | 8.3 | 22.9 | 40.4 | 17.5 | 49.2 |
| Tran, 2020 [81] | 16 | 3 | 1 | 6 | 57.7 | 197 | 87 | |||||
| Wang, 2021 [50] | 16 | 3 | 2 | 5 | 80 | 12.5 | ||||||
| Xu–a, 2020 [82] Xu–b, 2020 [82] Xu–c, 2020 [82] |
15 15 15 |
3 3 3 |
2 2 2 |
5 5 5 |
51 51 51 |
235 210 227 |
66.1 70.5 72.2 |
20.9 19.5 19.4 |
11.5 9.5 8.4 |
12.35 10 8.4 |
0.85 0.5 0 |
33.25 29.5 27.8 |
| Yi, 2018 [83] | 16 | 3 | 2 | 5 | 53.56 | 110 | 13.6 | 61.8 | 20 | 24.5 | 4.5 | 86.4 |
a 1 = North America; 2 = Europe; 3 = Asia; 4 = South America; 5 = Africa; 6 = Australia/New Zealand; b 1 = inpatient; 2 = outpatient; 3 = patient in a palliative care setting; 4 = all; 5 = other; c 1 = >3 types of cancer; 2 = head and neck; 3 = oesophagus, 4 = bronchus/lung; 5 = breast; 6 = gastro-intestinal; 7 = prostate; 8 = other, urological; 9 = gynaecological; 10 = haematological; 11 = other; d moderate–severe pain; e none–mild pain.